Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review

Abstract

Most studies point towards an increased cardiovascular risk in PsA, broadly on a par with the risk level in rheumatoid arthritis, emphasising the need for similar cardiovascular risk management in both conditions. Further studies are needed to indicate whether inflammatory suppression or modification of traditional cardiovascular risk factors, or both, will reduce cardiovascular risk.

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

“…Studies on the prevalence of MetS in Turkey ranges from 26.5% to 42.6% (6)(7)(8). Recent studies have shown that the prevalence of MetS and cardiovascular diseases (CVDs) increases in patients with PsA and that CVDs are the most common cause of death in patients with PsA (9)(10)(11)(12)(13)(14). The aim of this study was to identify the prevalence of MetS and the degree of CVD risk in patients with PsA compared to patients with RA in a Turkish population.…”

Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study

“…However, these studies included a diverse range of study designs, including both primary and secondary care populations, and patients with both psoriasis and psoriatic arthritis [11]. Most recently, a large study from UK primary care found that major adverse cardiovascular events (MACE) were more common in PsA patients not prescribed a disease modifying antirheumatic drug (DMARD), but not in those using DMARDS, compared to controls [12].…”

The Predictive Factors of the Cardiovascular Infringement in the Rheumatoid Arthritis.

“…L'altération de la fonction endothéliale et l'augmentation de la rigidité artérielle et de l'épaisseur intimamédia, qui sont des facteurs prédictifs d'accident cardiovasculaire, ont été retrouvées chez les patients ayant une PR par rapport aux sujets contrôles dans des études transversales ou longitudinales (10). Il existe également une augmentation de la morbi-mortalité cardiovasculaire dans le rhumatisme psoriasique et la spondylarthrite ankylosante (SPA), du même ordre que celle observée dans la PR (11,12). La dyslipidémie observée dans la PR illustre les intrications entre l'inflammation et les facteurs de risque traditionnels.…”